http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amicus Therapeutics Announces First Quarter 2022 Financial Results
-
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
-
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
-
Amicus Therapeutics (FOLD) Issues New US Composition of Matter Patent for Galafold
-
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
-
Amicus Therapeutics (FOLD) Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
-
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
-
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
-
Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
-
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
-
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022
-
Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022
-
Amicus Therapeutics (FOLD) Reports Preliminary 2021 Revenue, Provides 2022 Strategic Outlook and Revenue Guidance
-
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
-
Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Amicus Therapeutics (FOLD) Announces EMA Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
-
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
-
Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference
-
Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
-
Amicus Therapeutics (FOLD) Announces Publication of Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
-
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
-
Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
-
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
-
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
-
Amicus Therapeutics (FOLD) Announces U.S. FDA Accepts Filings for its AT-GAA for the Treatment of Pompe Disease
-
Amicus Therapeutics (FOLD) and ARYA Sciences Acquisition Corp IV (ARYD) Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
-
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
-
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
-
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
-
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
-
Amicus Therapeutics (FOLD) Announces European Commission Approval of Galafold for Adolescents with Fabry Disease
-
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
-
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
-
Amicus Therapeutics (FOLD) Appoints Eiry W. Roberts, M.D. to its Board of Directors
-
Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors
-
Amicus Therapeutics (FOLD) Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
-
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
-
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
-
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
-
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
-
Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
-
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
-
Amicus Therapeutics (FOLD) Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
-
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
-
Amicus Therapeutics Recognized as a Great Place to Work® in Europe
-
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
-
Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference

